Loading publications…
The last 5 uploaded publications
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Pascal Vranckx, Marco Valgimigli, Peter Jüni, Christian W. Hamm, Philippe Gabríel Steg, Dik Heg, Gerrit Anne van Es, Eugène McFadden, Yoshinobu Onuma, Cokky van Meijeren, Ply Chichareon, Edouard Benit, Helge Möllmann, Luc Janssens, Maurizio Ferrario, Aris Moschovitis, Aleksander Żurakowski, Marcello Dominici, Robert‐Jan van Geuns, Kurt Huber, Ton Slagboom, Patrick W. Serruys, Stephan Windecker, Mohamed Abdellaoui, David Adlam, İbrahim Akın, Agustín Albarrán González-Trevilla, Manuel Almeida, Pedro A. Lemos, Adel Aminian, Richard Anderson, Rick Andreae, Michaël Angioı̈, Taku Asano, Emanuele Barbato, Peter Barlis, Pascal Barraud, Edouard Benit, Olivier F. Bertrand, Farzin Beygui, Leonardo Bolognese, Roberto Botelho, Coby Bouwman, Marco Bressers, Philippe Brunel, Paweł Buszman, Ian Buysschaert, Pedro Canas da Silva, Didier Carrié, Ángel Cequier, Ply Chichareon, Chun Chin Chang, Saqib Chowdhary, Carlos Collet, Antonio Colombo, James Cotton, Rui Cruz Ferreira, Salvatore Curello, Nick Curzen, Judith de Bot, Tone de Vreede, Georg Delle Karth, Lynn Dijksma, Marcello Dominici, István Édes, Éric Eeckhout, Ingo Eitel, József Faluközy, Farzin Fath‐Ordoubadi, Maurizio Ferrario, Géza Fontos, José Francisco Díaz Fernández, Edgard Freitas Quintella, Bernhard Frey, Guy Friedrich, Gavin Galasko, G. Gałuszka, Vasco Gama Ribeiro, Scot Garg, Giuseppe Gargiulo, Tobias Geisler, Валери Гелев, Art Ghandilyan, Javier Goicolea, Tommaso Gori, Felice Gragnano, Ana Guimarães, Christian W. Hamm, Michael Haude, Dik Heg, Pieter Heijke, Rosa Ana Hernández Antolín, David Hildick‐Smith, Dorien Hillen, Ina Hoekman, Sjoerd H. Hofma, Lene Holmvang, Stephen P. Hoole, Iván Horváth, Kurt Huber (2018). Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. The Lancet, 392(10151), pp. 940-949, DOI: 10.1016/s0140-6736(18)31858-0.
Article146 days agoA bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial
Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek, Ángel Cequier, Didier Carrié, Andrés Íñiguez, Marcello Dominici, René J. van der Schaaf, Michael Haude, Luc Wasungu, Susan Veldhof, Lei Peng, Peter Stæhr, Maik J. Grundeken, Yuki Ishibashi, Héctor M. García‐García, Yoshinobu Onuma (2014). A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. The Lancet, 385(9962), pp. 43-54, DOI: 10.1016/s0140-6736(14)61455-0.
Article146 days agoComparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial
Patrick W. Serruys, Bernard Chevalier, Yohei Sotomi, Ángel Cequier, Didier Carrié, Jan J. Piek, Ad J. van Boven, Marcello Dominici, Dariusz Dudek, Dougal McClean, Steffen Helqvist, Michael Haude, Sebastian Reith, Manuel Almeida, Gianluca Campo, Andrés Íñiguez, Manel Sabaté, Stephan Windecker, Yoshinobu Onuma (2016). Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. The Lancet, 388(10059), pp. 2479-2491, DOI: 10.1016/s0140-6736(16)32050-5.
Article146 days agoEverolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial
Manel Sabaté, Ángel Cequier, Andrés Íñiguez, Antonio Serra, Rosana Hernández‐Antolín, Vicente Mainar, Marco Valgimigli, Maurizio Tespili, Pieter den Heijer, Armando Bethencourt, Nicolás Vazquez, Joan Antoni Gómez‐Hospital, José Antonio Baz, Victoria Martín‐Yuste, Robert‐Jan van Geuns, Fernándo Alfonso, Pascual Bordes, Matteo Tebaldi, Mónica Masotti, Antonio Silvestro, Bianca Backx, Salvatore Brugaletta, Gerrit Anne van Es, Patrick W. Serruys (2012). Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. The Lancet, 380(9852), pp. 1482-1490, DOI: 10.1016/s0140-6736(12)61223-9.
Article146 days agoEverolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial
Manel Sabaté, Stephan Windecker, Andrés Íñiguez, Lisette Okkels Jensen, Ángel Cequier, Salvatore Brugaletta, Sjoerd H. Hofma, Lorenz Räber, Evald Høj Christiansen, Maarten J. Suttorp, Thomas Pilgrim, Gerrit Anne van Es, Yohei Sotomi, Héctor M. García‐García, Yoshinobu Onuma, Patrick W. Serruys (2015). Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial. European Heart Journal, 37(3), pp. 229-240, DOI: 10.1093/eurheartj/ehv500.
Article146 days ago